Korlym Articles
Cushing’s syndrome patients to receive safer drug options
22 February 2012
FDA approves first Cushing’s syndrome drug, Corcept’s Korlym
20 February 2012
Showing 1-3 of 3 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
